Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor: A Multicenter, Open-Label, Randomized Phase 3 Trial
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Cetuximab (Primary) ; Palbociclib (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 06 Jun 2023 Trial design, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 24 Apr 2023 Planned End Date changed from 30 Apr 2025 to 28 Feb 2027.
- 24 Apr 2023 Planned primary completion date changed from 30 Apr 2025 to 28 Feb 2027.